Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity

被引：39

作者：

Clynes, Raphael

机构：

[1] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

[2] Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2006年 / 20卷 / 03期

关键词：

D O I：

10.1016/j.hoc.2006.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Engineered antibody therapeutics have provided new treatment options in cancer. Genetic evidence in man and in the mouse suggests that Fc receptor (FcR) engagement contributes mechanistically to the therapeutic activity of naked antibodies. Preferential activation of activating FcRs and limited engagement of inhibitory FcRs enhance tumor responses in mouse models. Thus, engineered Fc domains with favorable affinities for specific FcR types may prove to be clinically superior. © 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：585 / 612

页数：28

相关论文

共 134 条

[1] Targeting apoptotic tumor cells to FcγR provides efficient and versatile vaccination against tumors by dendritic cells [J].

Akiyama, K ;

Ebihara, S ;

Yada, A ;

Matsumura, K ;

Aiba, S ;

Nukiwa, T ;

Takai, T .

JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :1641-1648

[2] Adding cytokines to monoclonal antibody therapy: Does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-Hodgkin lymphoma? [J].

Ansell, SM .

LEUKEMIA & LYMPHOMA, 2003, 44 (08) :1309-1315

[3] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma [J].

Ansell, SM ;

Witzig, TE ;

Kurtin, PJ ;

Sloan, JA ;

Jelinek, DF ;

Howell, KG ;

Markovic, SN ;

Habermann, TM ;

Klee, GG ;

Atherton, PJ ;

Erlichman, C .

BLOOD, 2002, 99 (01) :67-74

[4] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].

Bellosillo, B ;

Villamor, N ;

López-Guillermo, A ;

Marcé, S ;

Esteve, J ;

Campo, E ;

Colomer, D ;

Montserrat, E .

BLOOD, 2001, 98 (09) :2771-2777

[5] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].

Berinstein, NL ;

Grillo-Lopez, AJ ;

White, CA ;

Bence-Bruckler, I ;

Maloney, D ;

Czuczman, M ;

Green, D ;

Rosenberg, J ;

McLaughlin, P ;

Shen, D .

ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001

[6] The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma [J].

Bevaart, L ;

Jansen, MJH ;

van Vugt, MJ ;

Verbeek, JS ;

van de Winkel, JGJ ;

Leusen, JHW .

CANCER RESEARCH, 2006, 66 (03) :1261-1264

[7] PRODUCTION OF FUNCTIONAL CHIMAERIC MOUSE HUMAN-ANTIBODY [J].

BOULIANNE, GL ;

HOZUMI, N ;

SHULMAN, MJ .

NATURE, 1984, 312 (5995) :643-646

[8]

Carson WE, 2001, EUR J IMMUNOL, V31, P3016, DOI 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO

[9]

2-J

[10] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

← 1 2 3 4 5 6 7 8 9 10 →